Insight Molecular Diagnostics (IMDX) shares were over 10% higher premarket Monday after the company said its GraftAssure assay helped avoid overtreatment for a kidney transplant patient who developed a type of lymphoma.

The biotech company said the 33-year-old transplant patient had to end traditional immunosuppression for treatment and that GraftAssure molecular testing confirmed an absence of transplanted organ rejection throughout a treatment period with a novel CD19 CAR-T therapy.

Insight Molecular said the patient demonstrated "stable" graft function for approximately two years without immunosuppression and remained in remission, which suggests an "immune reset" due to treatment.

The company said the patient was being evaluated in a study conducted by Insight Molecular researchers and partners. It also said it believes the study positions GraftAssure as possibly vital in managing kidney transplant patients with certain cancers.